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ABSTRACT
OBJECTIVE: To analyze factors associated with low adherence to drug treatment for chronic 
diseases in Brazil.
METHODS: Analysis of data from Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso 
Racional de Medicamentos (PNAUM - Brazilian Survey on Access, Use and Promotion of Rational 
Use of Medicines), a population-based cross-sectional household survey, based on a probabilistic 
sample of the Brazilian population. We analyzed the association between low adherence to drug 
treatment measured by the Brief Medication Questionnaire and demographic, socioeconomic, 
health, care and prescription factors. We used Poisson regression model to estimate crude and 
adjusted prevalence ratios, their respective 95% confidence interval (95%CI) and p-value (Wald test).
RESULTS: The prevalence of low adherence to drug treatment for chronic diseases was 30.8% 
(95%CI 28.8-33.0). The highest prevalence of low adherence was associated with individuals: 
young adults; no education; resident in the Northeast and Midwest Regions of Brazil; paying 
part of the treatment; poor self-perceived health; three or more diseases; reported limitations 
caused by a chronic disease; using five drugs or more.
CONCLUSIONS: Low adherence to drug treatment for chronic diseases in Brazil is relevant, 
and regional and demographic differences and those related to patients’ health care and therapy 
regime require coordinated action between health professionals, researchers, managers and 
policy makers.
DESCRIPTORS: Patient Dropouts. Medication Adherence. Drugs of Continuous Use. Chronic 
Disease. Health Services Accessibility. Socioeconomic Factors. Health Surveys.
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INTRODUCTION
Noncommunicable diseases, a global health problem, are the target of various prevention 
and control programs and initiatives1. Many noncommunicable diseases can be controlled 
by the use of drugs, which, when available and properly used, lead to therapeutic success. 
An important factor that directly influences therapeutic outcomes is adherence to 
drug treatment, defined as the degree of agreement between a person’s behavior and 
professional guidance22.
Factors related to non-adherence to treatment described in the literature concern individual 
characteristics of patients, the actual disease, the drugs used and interaction between 
patients and health services, among others20. The characteristics of certain health conditions 
or therapies may lead to specific barriers to adherence. For some asymptomatic diseases 
such as high blood pressure, patients may have difficulty to use drugs regularly because of 
the lack of visible symptoms or understanding of the disease’s behavior15. For illnesses that 
require complex regimes (polypharmacy, multiple daily administrations, difficulties with 
administration), such as asthma and diabetes, the actual daily difficulties associated with 
the use of drugs are an important barrier to adherence3.
According to the World Health Organization (WHO), non-adherence to long-term treatment 
in the population at large is around 50.0%20. In a systematic review summarizing studies 
published over 50 years, DiMatteo5 (2004) identified an average non-adherence rate of 24.8%.
Brazil lacks sufficient evidence on the prevalence of low adherence among patients with 
chronic diseases based on nationwide studies. The available studies used local or regional 
samples17, population subgroups (such as older adults)20, or focused on specific chronic 
diseases such as high blood pressure6,7,18. Therefore, studies that estimate treatment adherence 
among the Brazilian population with chronic diseases are important to support health policy 
and practice aimed at improving access to and rational use of drugs.
The aim of this study was to analyze factors associated with low adherence to drug treatment 
for chronic diseases in Brazil.
METHODS
The data analyzed in this study are from Pesquisa Nacional sobre Acesso, Utilização e Promoção 
do Uso Racional de Medicamentos (PNAUM – National Survey on Access, Use and Promotion 
of Rational Use of Medicines), a population-based cross-sectional household survey, based 
on a probabilistic sample of the Brazilian population. Data were collected from September 
2013 to February 2014. The study population lived in permanent private households in urban 
areas of Brazil, and included individuals of all ages. Face-to-face interviews were carried out 
in households using questionnaires, and data were collected and stored in electronic devices. 
The tools were developed by a group of expert researchers from Brazilian universities and 
standardized and tested before being administered.
The complex sampling process resulted in a sample that ensured national representation for 
the five Brazilian regions, stratified by gender and age groups. Further details on sampling and 
data collection can be found in the PNAUM methodology article13. This study included adults 
aged 20 or older who reported at least one chronic disease diagnosed at least six months prior 
to the interview (n = 14,358). The investigation on adherence to drug treatment included all 
subjects who reported medical indication for treatment and were using medication for the 
chronic diseases mentioned at the interview (n = 11,842).
To assess adherence reported by patients, we used the Brief Medication Questionnaire 
(BMQ), composed of three areas that identify barriers to adherence related to the regime, 
beliefs, and memories of the drug treatment. We used the BMQ2 version translated into 
Portuguese, which classifies individuals into four categories of adherence to treatment, 
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according to the number of positive responses in any of the areas: high adherence (none), 
likely high adherence (1), likely low adherence (2), and low adherence (3 or more). The 
outcome analyzed in this study was prevalence of low adherence to treatment, considered 
as a score of 2 or more in any field.
The variables related to demographic and socioeconomic characteristics were: gender 
( female; male); age group (20-39; 40-59; 60 and over); self-reported skin color (white, 
non-white), marital status (with partner; without partner); education reported in grades and 
reclassified in years of study (0, 1-8, 8 years or more); economic status according to Critério 
de Classificação Econômica Brazil (Brazilian Economic Classification Criterion) of Associação 
Brasileira de Empresas de Pesquisa (ABEP – Brazilian Association of Survey Companies [A/B; 
C; D/E]), geographic region of residence (North, Northeast, Southeast, South, Midwest) and 
whether the respondent had health insurance.
Regarding health care, we analyzed the number of hospitalizations and emergency visits in 
the previous year (none, one, two or more), if the individual visits and has a single doctor to 
treat the diseases, and free access to medicines (all drugs; any drug; no drugs).
Regarding perception of health and morbidities, the following variables were evaluated: 
number of chronic diseases reported (high blood pressure; diabetes; stroke; lung disease; 
depression; rheumatism; other chronic diseases lasting more than six months) grouped 
into one, two, three or more conditions; self-perceived health, analyzed in five categories 
(very poor; poor; average; good; very good); and reported limitations related to at least one 
chronic disease. Regarding drug use, we analyzed the number of drugs used (continuous or 
occasional) (1; 2; 3 or 4; 5 or more).
The analyses were performed with Stata version 11.0 software, using the appropriate set 
of svy commands to analyze complex samples and ensuring the necessary weighting, 
considering the sample design. Exploratory descriptive analysis was performed for all 
the variables involved in the study, presenting the relative frequencies and respective 95% 
confidence intervals (95%CI). For the univariate analysis, the BMQ score was dichotomized, 
considering as low adherence a score of two or more. In the crude analysis, the prevalence of 
low adherence to treatment was calculated for the categories of the independent variables, 
considering the dichotomous outcome. A 5% significance level was adopted.
We used Poisson regression model to estimate crude and adjusted prevalence ratios (PR) and 
95%CI, considering the effect of the sample design with Stata svy commands. We attempted 
to control possible confounding factors in the multivariate analysis, using a hierarchical 
analysis model (Figure). Variables with p < 0.20 were included in the multivariate model, 
and we adopted a significance level of 5% to retain variables in the model, with “backward” 
selection of variables. The statistical significance of prevalence ratios obtained in Poisson 
regression models was assessed by the Wald test.
The study was approved by the Comissão Nacional de Ética em Pesquisa (National Research 
Ethics Committee – Opinion 398,131, of September 6, 2013). All interviews were conducted 
after the respondents or their legal representatives had read and signed the consent form.
RESULTS
Table 1 shows the adherence classification according to BMQ. The prevalence of low 
adherence (dichotomized score) to drug treatment for chronic diseases in Brazil was 30.8% 
(95%CI 28.8-33.0) and only 2.6% (95%CI 2.1-3.2) of respondents were classified as adhering 
to prescribed therapies (no positive response in the evaluated areas).
The sample breakdown and prevalence of low adherence in relation to socioeconomic and 
demographic characteristics are shown in Table 2. Prevalence of low adherence (statistically 
significant) was higher in the following categories: younger individuals (20-39 years) and 
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those residing in the Northeast and Midwest Regions. Prevalence of low adherence was also 
higher, although not statistically significant, among individuals who were female, non-white, 
reported not having a partner and having no education, D/E economic status, and without 
health insurance.
The characteristics of individuals with low adherence to treatment related to health care, 
self-perception and morbidities, and the use of drugs, are presented in Table 3. Prevalence 
of low adherence was higher in those individuals who do not see a doctor to treat chronic 
diseases, although it was not statistically significant. On the other hand, individuals visiting 
more than one doctor to treat those diseases had a 47.0% higher likelihood of low adherence 
to treatment than those who had only one doctor. Those who had to pay part of the treatment, 
had two or more hospitalizations, or received emergency care in the previous year had an 
80.0% lower adherence to treatment, approximately.
1st level
2nd level
3rd level
Demographic characteristics Socioeconomic characteristics
Level of education
Socioeconomic status
Brazilian region
Health insurance
Sex
Age
Skin color
Marital status
Health care
Number of doctors visited to treat diseases
Visit to doctor or health service to treat chronic disease
Free access to chronic treatment
Number of hospitalizations in the previous 12 months
Number of emergency visits in the previous 12 months
Perception of health and morbidities Use of medicines
Self-perceived health
Number of chronic morbidities
Limitations caused by a 
chronic disease
Number of medicines drugs used
ADHERENCE TO TREATMENT
Figure 1. Hierarchical model for the analysis of factors associated to adherence to drug therapy for 
chronic diseases in Brazil. PNAUM, Brazil, 2014.
Table 1. Classification of adherence to treatment for chronic diseases by adults aged 20 or over in Brazila. 
PNAUM, Brazil, 2014. (N = 11,842)
BMQa %b 95%CI
Categorical score
Adherence 2.6 2.1–3.2
Likely adherence 66.6 64.4–68.7
Likely low adherence 17.0 15.5–18.6
Low adherence 13.8 12.7–15.1
Dichotomous BMQ score
Adherence or likely adherence 69.2 67.0–71.2
Likely low adherence or low adherence 30.8 28.8–33.0
a According to Brief Medication Questionnaire (BMQ).
b Percentage adjusted by sample weighting and post-stratification by age and gender.
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Self-perceived health was strongly associated with low adherence to treatment, i.e., the likelihood 
of low adherence was about three times higher in those with poor or very poor self-perceived 
health. Regarding the number of chronic diseases, among those with three or more, prevalence 
of low adherence was about double that of individuals with only one disease. Those who reported 
limitations caused by chronic diseases had about 80.0% lower adherence to treatment.
Regarding the therapy regimen used to treat reported chronic diseases, those who were taking five 
or more drugs had 2.4 times lower adherence to treatment than those who used only one drug.
Table 4 features the results of the crude and adjusted analyses. In the crude analysis, the 
variables skin color, marital status, economic status and seeing a doctor to treat chronic 
diseases were not statistically significant and therefore did not enter the adjusted analysis 
model. After adjustment for potential confounders in the multivariate analysis, the 
Table 2. Prevalence of low adherencea,b to treatment for chronic diseases by adults aged 20 or over in 
Brazil, by demographic and socioeconomic characteristics. PNAUM, Brazil, 2014. (N = 11,842)
Variable
Breakdown in sample Prevalence of low adherencec
%a 95%IC %a 95%IC
Demographic characteristics
Gender
Male 35.3 33.9–36.7 28.3 25.4–31.5
Female 64.7 63.3–66.1 32.1 29.9–34.4
Age (years)
20-39 15.0 13.6–16.6 38.6 33.1–44.5
40-59 42.8 41.1–44.4 30.3 27.8–33.0
≥ 60 42.2 40.4–44.0 28.7 26.5–31.0
Skin color
White 50.6 47.8–53.4 30.0 27.3–32.8
Non-white 49.4 46.6–52.2 31.4 28.9–34.0
Marital status
With partner 61.4 59.8–62.9 30.5 28.3–32.8
Without partner 38.6 37.1–40.2 31.6 28.9–34.5
Socioeconomic characteristics
Level of education (years of study)
No education 15.0 13.7–16.4 35.5 31.5–39.8
1 to 8 years 43.1 41.2–45.0 28.5 25.8–31.3
≥ 8 years 41.8 40.0–43.7 31.7 29.3–34.2
Economic status ABEPd
A/B 24.6 22.3–27.0 30.6 26.9–34.6
C 54.8 52.9–56.7 30.3 28.0–32.7
D/E 20.7 18.9–22.5 32.6 29.2–36.2
Brazilian region
North 4.2 3.2–5.3 22.7 18.8–27.1
Northeast 20.6 16.8–25.0 38.1 35.1–41.2
Southeast 51.9 46.0–57.8 29.2 25.7–33.0
South 15.7 12.7–19.3 26.8 24.5–29.2
Midwest 7.7 6.0–9.8 35.5 31.6–39.6
Health plan
Yes 28.4 26.0–31.0 29.0 26.1–32.1
No 71.6 69.0–74.0 31.6 29.3–34.0
Total 30.8 28.8–33.0
a According to Brief Medication Questionnaire (BMQ).
b Percentage adjusted by sample weighting and post-stratification by age and gender.
c Non-adherence = low adherence according to BMQ (2 or more positive answers).
d According to Critério de Classificação Econômica Brasil 2013 – ABEP (www.abep.org).
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variables gender, level of education, number of hospitalizations in the last 12 months and 
self-perceived health lost their statistical significance. The following remained associated 
with low adherence to treatment for chronic diseases after the adjusted analysis: age, region, 
health insurance, number of doctors seen to treat chronic diseases, free access to therapy, 
number of emergency visits in the last 12 months, number of chronic diseases, limitation 
caused by disease and use of medicines.
Table 3. Prevalence of low adherencea,b to treatment for chronic diseases by adults aged 20 or over in 
Brazil, by characteristics related to health care, health perception, morbidities and drug use. PNAUM, 
Brazil, 2014. (N = 11,842)
Variable
Sample breakdown Prevalence of low adherence
% 95%IC % 95%IC
Health system characteristics
Visits doctor to treat chronic diseases
Yes 93.3 92.3–94.2 31.2 29.0–33.5
No 6.7 5.8–7.7 32.3 27.9–37.0
Number of doctors visited to treat chronic diseases
One 68.2 66.3–70.0 27.2 24.9–29.6
More than one 31.8 30.0–33.7 40.1 37.2–43.2
Free access to chronic drug therapy for chronic diseases
All free 46.9 44.5–49.2 25.4 23.0–28.1
Any free 20.3 19.1–21.5 46.6 42.7–50.7
None free 32.9 30.8–35.1 29.0 26.5–31.7
Number of hospitalizations in the previous 12 months
None 89.1 88.2–90.0 29.8 27.7–32.1
1 8.2 7.5–9.0 34.6 29.8–39.8
2 or more 2.7 2.2–3.2 51.8 42.7–60.9
Number of emergency visits in the previous 12 months
None 77.0 75.3–78.6 27.1 25.0–29.3
1 14.9 13.8–16.0 39.8 36.2–43.7
2 or more 8.1 7.2–9.1 50.0 44.6–55.4
Self-perceived health and morbidities
Self-perceived health
Very good 5.1 4.4–5.9 17.2 11.4–25.1
Good 45.6 43.6–47.6 25.0 22.6–27.7
Average 40.8 39.1–42.4 35.9 33.4–38.5
Poor 6.3 5.6–7.0 46.4 41.1–51.7
Very poor 2.3 1.9–2.7 49.6 39.7–59.5
Number of chronic diseases (comorbidities)
1 44.8 42.9–46.7 20.9 18.8–23.1
2 27.2 26.1–28.4 33.3 30.6–36.1
3 or more 28.0 26.3–29.7 44.2 41.0–47.4
Limitations due to chronic disease
No limitations 48.5 46.7–50.3 21.9 19.9–24.1
Limitations 51.5 49.7–53.3 39.5 36.9–42.2
Use of drugs
Number of drugs used (continuous or occasional)
1 34.6 33.2–36.0 20.6 18.2–23.2
2 26.0 24.7–27.3 26.4 23.8–29.2
3 to 4 26.0 24.8–27.3 38.9 35.6–42.4
5 or more 13.4 12.5–14.4 50.1 46.4–53.8
Total 30.8 28.8–33.0
a Percentage adjusted by sample weighting and post-stratification by age and gender.
b Non-adherence = low adherence according to the Brief Medication Questionnaire BMQ (2 or more 
positive answers).
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Table 4. Crude and adjusteda,b prevalence ratios of low adherence to treatment for chronic diseases by 
adults aged 20 or over in Brazil, by analyzed variables. PNAUM, Brazil, 2014. (N = 11,842)
Variablec Crude analysis Adjusted analysis
PR 95%IC pd PR 95% IC Pd
Level 1
Demographic characteristics
Gender 0.017
Male Ref
Female 1.13 1.02–1.25
Age (years) < 0.001 < 0.001
20-39 1.34 1.16–1.56 1.64 1.39-1.93
40-59 1.05 0.95–1.16 1.16 1.04-1.29
≥ 60 Ref
Skin color 0.383
White Ref
Non-white 1.04 0.94–1.16
Marital status 0.409
With partner Ref
Without partner 1.03 0.95–1.12
Socioeconomic characteristics
Level of education (years of study) 0.003
No education 1.11 0.97–1.27
1 to 8 years 0.89 0.81–0.99
≥ 8 years Ref
Economic status ABEPd 0.372
A/B Ref
C 0.98 0.86–1.12
D/E 1.06 0.90–1.25
Brazilian region < 0.001 < 0.001
North Ref
Northeast 1.68 1.37–2.05 1.33 1.10-1.61
Southeast 1.28 1.03–1.61 1.11 0.90-1.38
South 1.18 0.96–1.44 0.98 0.81-1.18
Midwest 1.56 1.26–1.94 1.21 1.00-1.47
Health plan 0.102 0.031
Yes 0.91 0.82–1.01 0.89 0.81-0.99
No Ref
Level 2
Health system characteristics
Visits doctor to treat chronic diseases 0,668
Yes Ref
No 0.96 0.82–1.12
Number of doctors visited to treat chronic diseases < 0.001 < 0.001
One Ref
More than one 1.47 1.34–1.61 1.16 1.06-1.26
Free access to drug therapy for chronic diseases < 0.001 < 0.001
All free Ref
Any free 1.83 1.64–2.04 1.32 1.18-1.49
None free 1.14 1.01–1.28 1.14 1.02-1.29
Number of hospitalizations in the previous 12 months < 0.001
None Ref
1 1.15 0.99–1.34
2 or more 1.73 1.44–2.08
Number of emergency visits in the previous 12 months < 0.001 < 0.001
None Ref
1 1.47 1.32–1.63 1.14 1.03-1.27
2 or more 1.84 1.63–2.09 1.32 1.18-1.48
Self-perceived health and morbidities
Self-perceived health < 0.001
Very good Ref
Good 1.45 0.99–2.12
Average 2.08 1.40–3.08
Poor 2.69 1.78–4.07
Very poor 2.88 1.91–4.32
Number of chronic diseases (comorbidities) < 0.001 < 0.001
1 Ref
2 1.59 1.41–1.79 1.28 1.10-1.48
3 or more 2.11 1.88–2.31 1.39 1.16-1.66
Limitations due to chronic disease < 0.001 < 0.001
No limitations Ref
Limitations 1.80 1.64–1.97 1.34 1.21-1.49
Level 3
Use of drugs
Number of drugs used to treat chronic diseases < 0,001 < 0,001
1 Ref
2 1,28 1,12–1,46 1,08 0,93–1,26
3 to 4 1,89 1,67–2,12 1,43 1,21–1,69
5 or more 2,43 2,14–2,76 1,61 1,34–1,94
a Non-adherence = low adherence according to BMQ (2 or more positive answers).
b According to the Brief Medication Questionnaire (BMQ).
c Variables grouped by entry in the adjusted analysis model.
d Wald test.
e According to Critério de Classificação Econômica Brasil 2013 – ABEP. Available from: http//www.abep.org.
8s
Adherence to chronic disease treatment in Brazil Tavares NUL et al.
DOI:10.1590/S1518-8787.2016050006150
DISCUSSION
Adherence is a multidimensional phenomenon determined by the interaction of a set of 
factors that affect people’s behavior and ability to follow treatment22. This study evaluated 
for the first time the factors associated with low adherence to treatment for chronic diseases 
in a representative sample of the Brazilian population aged 20 or more, contributing to build 
evidence on the subject to guide intervention strategies to improve treatment adherence 
among these patients.
About a third of the adult population showed low adherence to drug treatment for chronic 
diseases, a result similar to the systematic review that summarized data from international 
studies on the subject published over 50 years (1948 to 1998)5. Previous national studies 
showed great variability in prevalence, ranging from 17.0% to 63.5%6,7,17,18,20, but comparing 
results requires care because of the significant differences between studies in range of 
samples (local or regional), population subgroups, or focus on specific chronic diseases, 
such as high blood pressure.
The relationship between socioeconomic factors, such as income and education, 
and treatment adherence is widely investigated and previous studies have found an 
association between these variables and adherence, especially in chronic diseases5. 
In this study, low adherence to treatment was higher in individuals with lower levels of 
educationa, showing that this is a factor that must be considered in health care. Such 
patients require guidance regarding treatment to better understand the prescribed 
therapy regimens. On the other hand, economic status was not associated with the 
treatment of chronic diseases in Brazil.
Regarding demographic factors, the literature suggests that individuals who are young, 
male, and black show lower adherence to treatment 7,9. Our findings indicate that, among 
the Brazilian population, there is no significant difference between men and women, but 
younger people show lower adherence to treatment.
Residents of the Northeast and Midwest Regions had greater prevalence of low adherence 
to treatment than other regions, a result previously found by a study that evaluated the 
prevalence and factors associated with the non-use of continuous drugs among individuals 
who reported diagnosis of high blood pressure in the Pesquisa Nacional de Domicílios 
PNAD-20086 (National Household Sample Survey).
Regarding the characteristics related to the health of individuals, very poor self-perceived 
health was positively associated with low adherence to treatment in patients treating chronic 
diseases. A meta-analysis described that patients with better self-perceived health have 
better adherence to treatment, which can help reduce the worsening of patients, especially 
those afflicted with chronic diseases4.
The demographic transition we are currently experiencing, with an increase in the 
number of chronic diseases, has led to a growing use of medicines, especially among 
older adults20. In this study, we found a strong association between higher number of 
chronic diseases and low adherence. The explanation is that the simultaneous treatment 
of many chronic health conditions can result in polypharmacy, complex regimens in 
which medicine is taken many times a day, involving drug risks and predisposition 
to non-adherence10,22. Wang et al. (2005) described a significant reduction in the use 
of antihypertensive drugs in older patients with high blood pressure who have a high 
prevalence of comorbidities, reinforcing the impact of polypharmacy in adherence to 
treatment for chronic conditions21.
Another factor described as one of the most important related to treatment adherence is 
medication costs11,18. A meta-analysis showed an 11.0% higher likelihood of non-adherence 
to medication in populations with health insurance who had to pay part of their 
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medication costs, which may burden the public health system by increasing expenses from 
hospitalizations because of non-adherence to essential drugs19.
In Brazil, patients have free access through the Brazilian Unified Health System (SUS) 
to a list of essential medicines, with emphasis on the treatment of the most prevalent 
diseases, such as chronic diseases. However, a study that evaluated the availability 
of drugs in public health units in the country found low availability of drugs in all 
population strata12. In this study, the highest prevalence of low adherence to treatment 
was found among individuals who had to pay part of their treatment compared to those 
who had free access to all medicines needed to treat reported chronic diseases. This 
finding reinforces the fact that drugs not provided by SUS can lead users to abandon 
prescribed treatments for not being able to buy them in the private sector with their 
own resources20.
Regarding therapy regimens, the amount of prescribed drugs, the therapy schedule and 
the side effects are also associated with non-adherence16. The complexity of the therapy 
schedule, where the most relevant element is the number of prescribed drugs, also seems 
to contribute greatly to adherence to treatment8. In this study, individuals who used three or 
more drugs had a higher prevalence of low adherence to treatment, reinforcing this aspect 
as an important negative predictor of adherence to treatment.
Among the strategies to improve adherence are patient education, better treatment 
regimens and better communication between physicians and other health professionals 
and patients15. We noted in this study that individuals who reported seeing more than 
one doctor to treat their chronic diseases had a higher prevalence of low adherence to 
treatment, suggesting flaws in the whole care process. A recent systematic review shows 
that most of the current methods to improve adherence to treatment for chronic health 
problems are complex and ineffective. This shows the need for progress in this field, 
including improvement in the design of long-term viable interventions, objective adherence 
measures, and research capability, which should be sufficient to detect improvements in 
clinical outcomes of patients14.
The study’s limitations include the use of self-reporting to measure adherence to drug therapy, 
which is subject to measurement bias, and the actual cross-sectional design, which does not 
identify changes in health status, treatment regimens and other factors that can influence 
the behavior of patients’ adherence to treatment over time4. Moreover, the great variability 
of methods, tools and recall periods used to measure adherence limits the comparability 
of results. Despite the limitations, we were able to estimate in an unprecedented manner 
the factors associated with low adherence to drug therapy for chronic diseases in Brazil, 
contributing to the production of evidence to support the guidance of interventions 
addressing the subject in the country.
The results indicate that low adherence to drug treatment for chronic diseases in Brazil 
is relevant, and that regional and demographic differences and those related to patients’ 
health care and therapy regimen require coordinated action between health professionals, 
researchers, managers and policy makers.
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